News | May 02, 2014

UMC Utrecht, Quirem Medical Team Up to Develop Holmium Microspheres for Image-Guided Cancer Treatment

Accumulation of holmium in the liver before and after treatment

May 2, 2014 — The University Medical Center (UMC) Utrecht and Quirem Medical, both in the Netherlands, announced they will be working closely together to maximize the benefits of using holmium microspheres to treat liver cancer patients worldwide. The unique properties of holmium microspheres will enable effective treatment planning and dosimetry in treatment evaluation, thereby further improving the results of patients who undergo radioembolization.

The collaboration will cover ongoing and future clinical research, grant applications, the production of holmium microspheres and the application for CE marking. Financial details of the deal were not disclosed.


Image-Guided Radioembolization of Liver Tumors

Holmium microspheres are unique in that they can easily be seen on either a SPECT (single-photon emission computed tomography) or an MRI (magnetic resonance imaging) scan, allowing the doctor to establish whether the microspheres are doing their work in the right place in the body. There are two stages to a treatment using holmium microspheres: Administering a safe low dosage first, the doctor ascertains whether the radioactivity is accumulating properly in the liver. If it is, a higher dosage is administered. Holmium treatment is currently only applied in a palliative care setting


Clinical research

The results of a phase I clinical study (HEPAR I) were published in Lancet Oncology in 2012. As part of that study, UMC Utrecht researchers treated 15 patients and found that the treatment was safe. A clinical study (the HEPAR II study) on the effectiveness and to collect further support for the safety of the treatment is currently ongoing. This study will see 40 new patients being treated at UMC Utrecht.

Maurice van den Bosch, M.D., Ph.D., an interventional radiologist at UMC Utrecht, said, “To transform academic research in medicine from new and exciting ideas into innovations that can make a real difference to how we treat patients requires the long and firm commitment of both public and private partners. In Quirem Medical we have found a strong and dedicated partner that will further expedite the use of our research efforts in the field of minimally invasive, image-guided cancer treatments.”

Jan Sigger, CEO of Quirem Medical, added, “We are very pleased to have UMC Utrecht as our collaboration partner for the further development of the holmium radioembolization procedure. UMC Utrecht’s strong imaging and interventional capabilities are very much in line with the options that QuiremSpheres can provide to improve the effectiveness of the radioembolization procedure and, as a result, patient outcome.”

Quirem Medical is an emerging medical device company that seeks to develop the next generation of microspheres for the targeted interventional treatment of liver malignancies. It founded in 2013 as a UMC Utrecht spin-off.

For more information: www.umcutrecht.nl

Related Content

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
Penn Medicine to Host Fourth Annual Proton Therapy Training Course
News | Proton Therapy | August 30, 2017
August 30, 2017 — IBA (Ion Beam Applications S.A.) and the Department of Radiation Oncology at Penn Medicine, in part
Overlay Init